First-Line XELOX Plus Bevacizumab Followed by XELOX Plus Bevacizumab or Single-Agent Bevacizumab as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: The Phase III MACRO TTD StudyEduardo Díaz‐Rubio, María José Safont, Purificación Martínez de Prado et al.|The Oncologist|2012Cited by 213
Circulating Tumor Cell Count Is a Prognostic Factor in Metastatic Colorectal Cancer Patients Receiving First-Line Chemotherapy Plus Bevacizumab: A Spanish Cooperative Group for the Treatment of Digestive Tumors StudyJavier Sastre, Eduardo Díaz‐Rubio, M.L. Maestro et al.|The Oncologist|2012Cited by 88
First-Line XELOX Plus Bevacizumab Followed by XELOX Plus Bevacizumab or Single-Agent Bevacizumab as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: The Phase III MACRO TTD StudyEduardo Díaz‐Rubio, Enrique Aranda, Auxiliadora Gómez‐España et al.|Unknown|2012Cited by 25
Effect of pharmacogenetic-based selection of first-line chemotherapy on response rate and R0 surgery in metastatic CRC patients.Albert Abad, Eva Martinez‐Balibrea, José María Viéitez et al.|Journal of Clinical Oncology|2016Cited by 2